trial · primary record
Raludotatug Deruxtecan
Ovarian Cancer Recurrent
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 605 |
| Primary completion | 2031-02-07 |
| Primary endpoint | Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0) |
| Registry ID | NCT06843447 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:38.694Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06843447
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.